Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00062322 · ClinicalTrials.gov registry record · Phase 1
Neoadjuvant Chemoradiotherapy Followed By Surgery in Treating Patients With Limited-Stage Small Cell Lung Cancer
A Phase 1 study, sponsored by Fox Chase Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00062322: Completed Phase 1 study, sponsored by Fox Chase Cancer Center.
NCT00062322 is a Phase 1 study that has completed, run by Fox Chase Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00062322, a Phase 1 study, has completed, sponsored by Fox Chase Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy such as irinotecan and cisplatin use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Irinotecan and cisplatin may also make the tumor cells more sensitive to radiation therapy. Combining chemotherapy with radiation therapy before surgery may shrink the tumor so that it can be removed during surgery. PURPOSE: This phase I trial is studying the side effects of neoadjuvant radiation therapy given together with irinotecan and cisplatin followed by surgery in treating patients with limited-stage small cell lung cancer.
Interventions
- DRUG cisplatin
- PROCEDURE conventional surgery
- RADIATION radiation therapy
- DRUG irinotecan hydrochloride
- PROCEDURE neoadjuvant therapy
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-02 |
| Est. Completion | 2009-10 |
| Phase | Phase 1 |
What the finished NCT00062322 record still lists
NCT00062322 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 5 interventions - of which cisplatin is the first listed.
NCT00062322 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00062322 about?
NCT00062322 is a clinical study titled "Neoadjuvant Chemoradiotherapy Followed By Surgery in Treating Patients With Limited-Stage Small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy such as irinotecan and cisplatin use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Irinotecan and cisplatin may also make the tumor cells more sensitive to radiation...
What is the current status of trial NCT00062322?
This trial is currently completed. It is a Phase 1 study. The study started on 2003-02. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00062322?
The interventions under investigation include: cisplatin (DRUG), conventional surgery (PROCEDURE), radiation therapy (RADIATION), irinotecan hydrochloride (DRUG), neoadjuvant therapy (PROCEDURE).
Who is sponsoring clinical trial NCT00062322?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia